Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female inpatients 18 to 65 years of age~* Meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV) criteria for bipolar I disorder, acute manic or mixed episode~* Having a total Young Mania Rating Scale (YMRS) score \>= 20 and a score of at least 4 on two of the following YMRS items:~  * Irritability,~ * Speech,~ * Content, and~ * Disruptive/Aggressive Behavior~Exclusion Criteria:~* Patients who exhibit abnormalities on physical examination, have abnormal vital-signs, electrocardiogram (ECG), or clinical laboratory values \[such as thyroid-stimulating hormone (TSH)\].~* Patients with Montgomery-Åsberg Depression Rating Scale (MADRS) total score \>= 18 at Visit 2.~* Patients experiencing first manic episode.~* Patients that have received electroconvulsive therapy (ECT) or a depot neuroleptic in the 3 months prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine (Type: EXPERIMENTAL): Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).